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ProteomicsLung cancer is themost frequent cause of cancer-related deathworld-wide. Radiotherapy alone or in conjunction
with chemotherapy is the standard treatment for locally advanced non-small cell lung cancer (NSCLC). Currently
there is no predictive marker with clinical utility to guide treatment decisions in NSCLC patients undergoing ra-
diotherapy. Identiﬁcation of such markers would allow treatment options to be considered for more effective
therapy. To enable the identiﬁcation of appropriate protein biomarkers, plasma samples were collected from pa-
tients with non-small cell lung cancer before and during radiotherapy for longitudinal comparison following a
protocol that carries sufﬁcient power for effective discovery proteomics. Plasma samples from patients pre-
and during radiotherapy who had survived N18 mo were compared to the same time points from patients
who survived b14mousing an 8 channel isobaric tagging tandemmass spectrometry discovery proteomics plat-
form. Over 650 proteins were detected and relatively quantiﬁed. Proteins which showed a change during radio-
therapy were selected for validation using an orthogonal antibody-based approach. Two of these proteins were
veriﬁed in a separate patient cohort: values of CRP and LRG1 combined gave a highly signiﬁcant indication of ex-
tended survival post one week of radiotherapy treatment.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In the era of personalised medicine, biomarkers are required for the
stratiﬁcation of patients allowing therapy to be tailored. This could in-
clude molecular histology of disease to allow driver mutation targeted
therapy, for example EGFR tyrosine kinase inhibitors for lung cancer pa-
tients (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004). Biomarkers
which can be used as early markers of response to treatment would be
particularly useful in the clinic as well as in drug development, allowingryonic antigen; CRP, C-reactive
R, false discovery rate; IL-6,
tequantiﬁcation;LBP, lipopoly-
coprotein;mo,months;MS/MS,
ncer; PCA, principal component
arcinoma;TEAB, triethylammo-
r; v/v, volume/volume.
. Whetton).
. This is an open access article underpatients therapy to be tailored as early as possible (Beretta, 2007). To be
used routinely in the clinic, a biomarkerwould have to bemeasurable in
a non-invasive readily accessible tissue or bioﬂuid. Plasma as well as
urine is routinely used in clinics for the diagnosis of a variety of diseases.
For example, monitoring prostate speciﬁc antigen levels in blood has
been used for screening and monitoring progression of prostate cancer
(reviewed in Lilja et al., 2008).
Amajor issue for identiﬁcation of protein biomarkers is the high dy-
namic range of protein content in plasma (of the order of 1010 Polanski
and Anderson, 2007) that canmakemask lower abundance proteins re-
ducing the opportunity for detection with current instrumentation.
However advances in mass spectrometry and liquid chromatography
coupled to the depletion of highly abundant proteins have allowed
the plasma proteome to be investigated with approximately 6 orders
of magnitude penetration allowing identiﬁcation of so called tissue
leakage proteins which are predicted to be rich in biomarkers
(Rodriguez-Suarez and Whetton, 2013; Zhou et al., 2012). Anotherthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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between individuals in a population and in an individual over time.
We have previously published an analysis showing thatwith the appro-
priate use of longitudinal samples our isobaric tagging plasma proteo-
mics workﬂow can be used to identify biomarkers from clinical
studies with as few as three patients per group with a power of 0.8 for
the 70% least variant proteins (Zhou et al., 2012). We have coupled
this approach to our newly published bioinformatics technique which
more accurately estimates speciﬁc protein technical variation, this addi-
tional modelling allows more proteins to be identiﬁed as differentially
expressed with sufﬁcient power (Zhou et al., 2013). To show the utility
of these methodologies we have investigated if plasma markers with
clinical utility can be identiﬁed in non-small cell lung cancer (NSCLC)
patients undergoing radical radiotherapy in a deliberately small cohort
(3 vs 3) using a longitudinal sampling approach. Two baseline samples
prior to the start of radiotherapy were analysed from each patient,
allowing the baseline variation of each protein to be assessed, and
thus signiﬁcant changes during radiotherapy identiﬁed. These changes
were then validated in a second independent cohort of twenty three pa-
tients using a second methodology.
Patients diagnosed with lung cancer have a 5 year survival rate of
b10% in Britain (Parkin et al., 2005). Globally there are over 1.2 million
deaths related to lung cancer per annum (Crino et al., 2010). Surgery
remains the mainstay curative treatment for this disease. However
the majority of patients present with disease that is too advanced to
be resected or have multiple comorbidities precluding surgery. As a
consequence radical radiotherapy, either alone or combined with
chemotherapy, plays a major role in the treatment of patients with
locally advanced lung cancer (Crino et al., 2010). Radiotherapy is
known to cause acute and late toxicity in patients due to damage to
surrounding normal tissue. An example of thoracic radiation toxicity
is pneumonitis and pulmonary ﬁbrosis which can be life threatening
and can affect patients' quality of life and treatment outcome
(reviewed in Abratt and Morgan, 2002). Therefore assessment of re-
sponse to treatment such as radical radiotherapy is a valid and useful
contribution to determining treatment options in those undergoing
radical radiotherapy. We therefore considered if we can ﬁnd predic-
tive factors for survival after radical radiotherapy by use of our pro-
teomics pipeline.
Here we report on the proteomic analysis of samples from the
prospective study, RADAR, in which patients with small cell lung
cancer or NSCLC who are treated with radical radiotherapy are asked to
donate blood for research into toxicity and predicting outcome to treat-
ment. The materials collected for this study were longitudinal in nature
with samples taken prior to the radiotherapy and during treatment. This
allowed us to look at proteins which can act as predictive markers of sur-
vival early in the radiotherapy treatment using global discovery proteo-
mics. The results of this proteomic analysis are detailed below with
potential markers identiﬁed and validated in an independent cohort.
2. Materials and Methods
2.1. Sample Collection
Blood was collected from donors in lithium heparin coated tubes
and centrifuged within 30 min of collection at 2500 ×g for 15 min at
4 °C before aliquots of the plasma layer were stored at−80 °C. Samples
were collected at the following time points for each patient; before RT,
during RT (days 2, 3, 8, then weekly) and on completion after RT
(months 1, 3, 6) (Fig. 1). Blood sampleswere taken from 29 randomised
patients with lung cancer enrolled in the RADAR study at the Christie
Hospital, Manchester, UK following written informed consent with
ethical approval from the Central Manchester Local Research Ethics
Committee. This proteomic analysis was undertaken on two samples
per patient collected prior to the start of radiotherapy and a third sam-
ple on day 8 of the treatment regimen.2.2. Proteomic Workﬂow and Experimental Setup
The experiment and workﬂow was carried out as in Fig. 1. A 50 μl
aliquot of each sample in the study was pooled and used as a pooled in-
ternal control sample, analysed in duplicate in each isobaric tagging for
relative and absolute quantiﬁcation (iTRAQ) experiment to test techni-
cal variation. Each iTRAQ experiment consisted of two internal control
samples (channels 119 and 121) and six samples from two patients
randomised into the remaining channels. The study used three iTRAQ
experiments to analyse samples from six patients.2.3. Protein Depletion, Digestion and Labelling
Abundant proteins were removed from plasma using an Agilent
Mars14 chromatography column following themanufacturers' protocol
(Agilent, Palo Alto, CA, USA). Depleted samples were concentrated and
exchanged into 1 M triethyl ammonium bicarbonate (TEAB) using
4 ml spin concentrators with a 5 KDa molecular weight cutoff ﬁlter
(Agilent Palo Alto, CA, USA) as permanufacturer's instructions. The pro-
tein concentration in buffer-exchanged samples was measured using
Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA, USA). 50 μg of
each sample was reducedwith the addition of 1/10th of the sample vol-
ume of 50 mM tris(2-carboxyethyl)phosphine for 1 h at 60 °C. Cysteine
residues were then alkylated by the addition of 1/20th of the total sam-
ple volume of 200 mMmethyl thiomethanesulfonate (in isopropanol)
before incubation for 10min at room temperature. Proteinwas digested
by the addition of 5 μg of porcine trypsin (Promega, Madison,WI, USA),
followed by overnight incubation at 37 °C. The digested protein samples
were isobarically tagged with 8plex iTRAQ reagents according to the
manufacturers' instructions (ABSCIEX, Framingham,MA, USA). After la-
belling the sampleswere dried at 60 °C in aDNAconcentrator (GeneVac,
Ipswich, UK) and then stored at−20 °C.2.4. High pH Reverse Phase Chromatography
Isobarically tagged samples were reconstituted in 100 μl of buffer A
(99.5%water adjusted topH10.5with ammoniumhydroxide) and appro-
priate samples pooled prior to being loaded onto a 100 mm × 4.6 mm
3 μm C18 HPLC columns (Agilent Palo Alto, CA, USA). Peptides were
eluted by the application of a linear 30 min gradient up to 50% buffer B
(Acetonitrile, 0.1% (v/v) ammonium hydroxide) with 70 × 15 s fractions
collected from 4 min. Fractions were dried in a DNA concentrator
(GeneVac Ipswich, UK) at 60 °C and stored at−20 °C.2.5. Mass Spectrometry (MS/MS)
Samples were reconstituted in 30 μl of samples loading buffer
(20 mM citric acid, 2% (v/v) acetonitrile and 0.1% (v/v) formic acid).
3 μl of each fraction was then loaded onto a nanoACQUITY UPLC Sym-
metry C18 Trap, 5 μm, 180 μm × 20 mm (Waters, Milford, MA, USA) at
15 μl/min of 3% (v/v) acetonitrile, 0.1% (v/v) formic acid for 5 min. Ana-
lytical separation of the peptides was performed using nanoACQUITY
UPLC BEH C18 Column, 1.7 μm, 75 μm × 250 mm (Waters, Milford,
MA, USA). Brieﬂy, peptides were separated over a 91min solvent gradi-
ent from 3% (v/v) acetonitrile, 0.1% (v/v) formic acid to 40% (v/v) aceto-
nitrile, 0.1% (v/v) formic acid. MS was carried out by a TripleTOF 5600
(ABSciex, Framingham, MA, USA) set up to analyse the top 20 ions by
MS/MS per MS scan. The MS scanned between 350 and 1250 m/z with
an accumulation time of 250 ms. Ions were only selected for MS/MS if
they were over 150 counts per a second and had a charge state of be-
tween 2 and 5, ions previously selected were excluded for 30 s. The
MS/MSwas carried out in high sensitivitymodewith 100ms accumula-
tion time and a rolling collision energy based upon mass and charge
with a spread of 20. The MS/MS scanned between 100 and 1600 m/z.
Fig. 1. Schematic representation of study design and experimental workﬂow. (a) Therapeutic plan, two baseline samples are collected prior to the start of RT (T1 and T2). RT is delivered
over 6 weeks (green boxes) with a sample collected duringweek 2 (T3). After treatment patient survival was followed and patients were retrospectively assigned to either the b14mo or
N18mo survival groups. (b) Experimental plan and workﬂow for identiﬁcation and relative quantiﬁcation of plasma proteins. Proteins were depleted of high abundance proteins using a
MARS 14 depletion system followed by digestion with trypsin and labelling with the correct iTRAQ reagent. Each iTRAQ 8 plex was designed to contain the samples from 2 patients (one
b14mo one N18mo) A portion of all samples included in the discovery cohortwere collected into a pool samplewhichwasused to assess technical variation and allow comparisons across
isobaric tagging experiments. Peptideswere fractionated prior tomass spectrometry by 2-dimensional reverse phase liquid chromatography, the 1st dimension at pH 10.5 and the second
at pH 3. The mass spectrometry was run with IDA methods and the raw result ﬁles analysed by Protein Pilot. Protein quantiﬁcation is then reconstituted from high conﬁdence peptide
spectral matches and the proteins with elevated levels postradiotherapy identiﬁed.
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All MS/MS data were submitted to ProteinPilot software version 4.5
(ABSCIEX, Framingham, MA, USA) for database searching and iTRAQ re-
porter ion quantiﬁcation. Searches were performed against the Ensembl
human core 63 data base (85285 entries, downloaded 2012)with the fol-
lowing settings; cysteine alkylation with methanethiosulfonate (MMTS),
biologicalmodiﬁcations allowed and trypsin as the digestion enzyme. The
search was carried out with default settings and thus the cleavage speci-
ﬁcity, number of missed cleavages and mass tolerances were preset. The
false discovery rate (FDR) of protein identiﬁcation was controlled using
a target-decoy searching strategy (Elias and Gygi, 2007) where forward
and reverse sequences from a database were in equal competition to be
the highest ranking identiﬁcation for each spectrum. The q-value ap-
proach (Storey and Tibshirani, 2003) was then applied to deﬁne a cut-
off for peptide conﬁdence so that the control criteria of FDR can be
met. The maximum allowed FDR for protein identiﬁcation was set to
5%. The iTRAQ data has been deposited to the ProteomeXchange Con-
sortium (Vizcaino et al., 2014) via the PRIDE partner repository with
the dataset identiﬁer PXD001052 and uploaded to http://www.scalpl.
org/hank/MatchPage;jsessionid=80bf3253ea31befd6e36c2ce957a?0
under RADAR. Guide to the use of this database can be found in Supple-
mentary Document 1.
2.7. Identifying Proteins That Are Differentially Expressed
Based on two baseline samples and one post-treatment sample per
patientwe aimed to discover proteins thatwere differentially expressed
in response to radiotherapy, and in particular, to discover those that
allowed discrimination between patients with good and poor survival.
Aspects of data variation were investigated in order to assign reliable
statistical signiﬁcance to the observed protein changes.Technical variation inherent in each iTRAQ experiment was estimat-
ed from the technical replicates included in the experiments, using the
method as described in the supplementary material. This method
allowed estimation of technical variation following a Normal distribu-
tion for each individual protein.
Within-person variation can be estimated by the changes between
the two baseline samples. These changes were measured as log ratios
and were considered to come from a combination of technical variation
and within-person variation, therefore:
var log
I2
I1
 
¼ varwithin person þ vartechnical
where I1 is the expression level at the ﬁrst baseline and I2 is the expres-
sion level at the second baseline. Three assumptions had to be adopted
to make the estimation of within-person variation valid:
1) There is no change in disease during the period fromwhich baseline
samples were taken.
2) Within-person variation didn't change in response to treatment,
i.e., once the variation was estimated using the baseline data it can
also be used in analysing the post-treatment data.
3)All proteins were assumed to follow a same Normal distribution. This
assumption was adopted because two baseline samples didn't allow
accurate estimation of within-person variation for each individual
protein. The distribution of the baseline variation was illustrated in
Supplementary Fig. 1 and the validity of the assumption is shown.
The methodology described above was adapted from previous pub-
lications (Zhou et al., 2012; Zhou et al., 2013).
Inter-person variation was estimated as following a unique Normal
distribution for each individual protein. If it was intended to ﬁnd pro-
teins that were differentially expressed following treatment, i.e. equal
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should be estimated using all available patients. Otherwise, if it was
intended to ﬁnd proteins that change differently in patients from differ-
ent cohort, inter-person variation had to be estimated separately for
each cohort of patients. Inter-person variation was estimated by
deducting technical variation and within-person variation from the ob-
served variation within the deﬁned cohort of patients, as published
(Zhou et al., 2012).
With the technical variation, within-person variation and inter-
person variation estimated for each protein, the statistical signiﬁcance
(p-values) of the observed changes on one protein can be readily de-
ﬁned. Proteins differentially expressed as a result of treatment were
identiﬁed according to the p-values, and a q-value approach (Storey
and Tibshirani, 2003) was applied for FDR control to ensure that only
the most conﬁdent identiﬁcations were retained for further validation.
The acute phase response pathway diagrams were generated
through the use of IPA (Ingenuity® Systems, www.ingenuity.com).
2.8. Veriﬁcation of Potential Biomarkers
Levels of target proteins were measured using commercial ELISA
kits, LRG1 (Demeditec, Germany), CRP (Invitrogen, Paisley, UK), LBP
(Abnova, Taipei City, Taiwan) following manufacturer's instructions.
IL6 was measured using the SearchLight Plus multiplex ELISA platform
(Aushon BioSystems, Boston, US) and was run using the method previ-
ously described (Backen et al., 2009). The veriﬁcation analysis was car-
ried out with the sample outcome blinded until data analysis. Statistical
analysis of the ELISA results was carried out using Graphpad Prism ver-
sion 6.04with signiﬁcance testing doneusing unpaired two tailedMann
Whitney test.
3. Results
3.1. Discovery Proteomics Using Longitudinal Samples FromNSCLC Patients
Undergoing Radiotherapy
The analysis of plasma frompatients and apparently healthy individ-
uals for identiﬁcation of potential biomarkers suffers from the heteroge-
neity of protein content in peripheral blood. We have shown that this
can be overcome by use of longitudinal samples, a reproducible plasma
preparation and isobaric tagging relative quantiﬁcationmass spectrom-
etry approach (Zhou et al., 2012).
The aim of the study was to identify proteins that signiﬁcantly
change during the ﬁrst ﬁve fractions of a course of radiotherapy as can-
didates for biomarkers of clinical beneﬁt from radiotherapy (Fig. 1a).
Plasma was collected to a standard operating procedure (see Materials
and Methods) from patients undergoing radical radiotherapy for lung
cancer treatment. Patients were classiﬁed into two groups (n = 3) de-
pendent on survival time: those living for b14 mo after treatment
(b14 month group); those living N18 mo after treatment (N18 month
group). The survival cut-offs were selected based on themedian surviv-
al of the study being 17mo. In both groups only squamous cell carcino-
ma patients with cancer related death were included and cases were
balanced for clinical factors as far as possible (Supplementary Table 1).
Two samples were collected prior to the start of radiotherapy enabling
the “baseline” variation of the proteins in a speciﬁc patient to be
assessed (see, Fig. 1a) and allowing smaller discovery cohorts of pa-
tients to be incorporated by design. The relative levels of proteins
weremeasured using 8-plex isobaric tagging of peptides which allowed
two patients to be analysed per MS run alongside a pooled reference, in
duplicate. The pooled reference allowed technical variation to be ob-
served, see Fig. 1b for proteomic workﬂow.
Relative quantiﬁcation on 658 proteins with a peptide FDR less the
0.05% on identiﬁcation (Supplementary Tables 3 and 4, 5) was derived.
The proteins identiﬁed were enriched for classical plasma protein path-
ways such as the complement cascade and acute phase responseproteins as is standardly seen in such studies. The within and between
person variation in plasma proteome during radiotherapy was investi-
gated using unsupervised principal component analysis (PCA) of pro-
teins quantiﬁed in all samples (Fig. 2a). By plotting the ﬁrst and
second principal component we showed that the largest variation in
the dataset was between different patients; as was anticipated from
our previous studies, validating our decision to use a workﬂow that
only permits longitudinal analysis. This PCA also demonstrated that
the two survival group (b14 mo and N18 mo) could be separated by
their ﬁrst two components, indicating that a proteomic biomarker
could be used to discriminate between these patients. We observed
that the largest intra-person variation after radiotherapy was observed
in the three patients with survival b14 mo (Fig. 2a). In order to investi-
gate the plasma proteome dataset further we generated a heat map
(Fig. 2b) taking the change during radiotherapy for each protein and pa-
tient. The clustering of protein did not show any pathways regulated in
either patients group.
Potential protein biomarkers for radiotherapy prognosis were iden-
tiﬁed using the statistical approach described in the methods. With the
technical and biological variation calculated for each protein, 9 putative
biomarkers had a signiﬁcant change during radiotherapy (Table 1). The
list of signiﬁcantly (p b 0.05) changing proteins was triaged further by
manual inspection of spectra and data, proteins showing consistent
changes across patients and low variation in the technical replicates of
the pooled standards were prioritised. Three proteins with elevated
levels during radiotherapy passed the manual inspection; C-reactive
protein (CRP), Lipopolysaccharide binding protein (LBP) and Leucine-
rich alpha-2-glycoprotein (LRG1). Fig. 2c, d, and e shows the ratio of
iTRAQ protein concentration values using the pooled plasma reference
standard as denominator for CRP, LBP and LRG1. Power analysis indicat-
ed that a power of more than 90% was reached, demonstrating that the
selected protein had a sound statistical evidence.
3.2. Veriﬁcation Analyses on Putative Biomarkers
To verify if the three shortlisted proteins are predictive of survival
during radiotherapy an additional cohort of 23 additional lung cancer
patients were analysed using enzyme linked immunosorbent assay
(ELISA) for CRP, LBP and LRG1. In this further part of the study other
lung cancer subtypes were included (Supplementary Table 3). Thus to
test if the effect is only speciﬁc to squamous cell carcinoma NSCLC
(SqCC), six patient samples from adenocarcinoma NSCLC (AC) and
small cell lung cancer (SCLC) patients respectively were included in
the veriﬁcation samples set aswell as eleven SqCC patients. Each patient
had a single pre-treatment sample as well as an early radiotherapy
treatment sample collected as for the SqCCNSCLC discovery proteomics
sample set using the same standard operating procedures for sample
collection and storage. The hypothesis that the putative biomarkers
mentioned above had relevance in diseases other than SqCC NSCLC,
like AC and SCLC, was tested by examining the level of each protein in
patients' plasma prior to and after radiotherapy (Fig. 3a). CRP showed
no signiﬁcant difference between any patient groups prior to therapy.
LRG1 levels in the plasma of SqCC patients (127 ± 11 mg/L mean ±
SD N = 11) was signiﬁcantly different to AC (78 ± 18 mg/L, mean ±
SD N = 6 p b 0.047) and SCLC (62 ± 8 mg/L mean ± SD N = 6,
p b 0.0003) prior to therapy. LBP levels in the plasma of SqCC patients
(33 ± 11 mg/L mean ± SD N = 11) was signiﬁcantly different to AC
(13 ± 7 mg/L mean ± SD N = 6, p b 0.0048) and SCLC (3 ± 1 mg/L
mean ± SD N = 6, p b 0.0031). Due to the differences seen in protein
levels between the different patient sets the effect of radiotherapy on
levels were only analysed between patients with the same histology.
The levels of all three proteins (CRP, LBP and LRG1) prior to radiothera-
py showed no signiﬁcant difference in the plasma of patients with poor
or good prognosis prior to radiotherapy (Fig. 3b). The level of each of the
proteins was compared for their changes during radiotherapy and only
SqCC patients showed any signiﬁcant difference in protein levels
Fig. 2. Discovery proteomics using longitudinal samples from NSCLC patients undergoing radiotherapy can distinguish patients with better survival. Patient samples were analysed using
an isobaric tagging 2D LCMS/MSmethod described in the Materials andMethods. (a) The levels of all proteins relative to a pooled reference, quantiﬁed in all isobaric taggingmass spec-
trometry experiments (157 proteins) were analysed by unsupervised principal component analysis of all patient sample and control pools. The ﬁrst and second principle components of
the datawere plotted in theﬁgurewith each data point an individual patient and time point. Colour represents an individual. Red, orange and purple survival N18mo, blue, green and cyan
survival b14 mo. The shape represents the time point; circle T1, square T2 and cross t3. (b) The log ratio of T3 to average of T1 and T2 of each protein for each patient was clustered. This
clusterwas visualised by plotting thedata ona heatmapwith colour indicating thedegreeof difference calculated (black is reduced and yellow is increased). (c–e) Scatter plots of the three
proteins (LRG1, CRP and LBP) changing signiﬁcantly in the b14mo survival patients (blue circle)when compared to the N18mo survival (red square). All signiﬁcance testswere two tailed
unpaired t-tests.
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regulated following radiotherapy, consistent with the MS/MS results,
but it showed no signiﬁcant difference between the N18 mo survival
SqCC patient group and the b14 mo survival SqCC patient group. The
level of CRP and LRG1 were both signiﬁcantly different in the SqCC
b14 mo survival group (CRP 48 ± 27 mg/L, LRG1 156 ± 19 mg/L
mean ± SD N = 5) compared to the SqCC N18 mo survival group
(CRP 8.5 ± 2 mg/L p = 0.0173, LRG1 94 ± 7 mg/L p = 0.0087,
mean± SD N= 6). Analysis of the levels seen before and during radio-
therapy levels for LRG1, LBP and CRP in adenocarcinoma and small cell
lung cancer showed no signiﬁcant difference in values (Fig. 3d). A
post-hoc power analysis of our two phase study (Mass spectrometry
identiﬁcation followed by ELISA veriﬁcation) was carried out based onTable 1
Discovery proteomics data for proteins which change in the plasma of patients during radiothe
after radiotherapy (independent of outcome) or signiﬁcantly different between survival group
in the table have been corrected for multiple comparisons.
Accession number Gene
symbol
Number of
peptides
Average log2 change
during radiotherapy —
all patients
P value
(for average ch
of all patients)
ENSP00000232003 HRG 472 −0.29 0.03
ENSP00000364494 APOC3 97 −0.68 0.06
ENSP00000441450 LBP 33 0.35 0.05
ENSP00000252491 APOC1 35 −0.37 0.25
ENSP00000246662 KRT9 92 0.14 0.62
ENSP00000310861 KRT2 41 −0.01 0.76
ENSP00000255030 CRP 63 1.13 0.20
ENSP00000302621 LRG1 334 0.34 0.18
ENSP00000252490 APOC2 45 −0.28 0.53simulation, a power of 82.6% was achieved, indicating that our results
are highly repeatable.
Since both CRP and LRG1 were found to be signiﬁcant predictive
markers of survival for squamous cell carcinoma patients undergoing
radiotherapy, we determined whether combining the levels of the
two proteins linearly could be of value. This increased the signiﬁcance
of the difference between the good and poor prognosis groups (p =
0.0043). Using a cut-off value of a combined level of 140 mg/L all pa-
tients could be stratiﬁed into the correct group of b14 mo and N18 mo
(Fig. 4a). LRG1 or CRP used in isolation does not result in this complete
stratiﬁcation. Gross tumour value was also available for ten of the pa-
tients (5 b 14 mo and 5 N 18 mo) analysed, since this has previously
been shown to be a predictive marker of survival for radiotherapy ofrapy. Table includes proteins with a signiﬁcant change (p value b 0.05) for either change
s (p value b 0.05). Ratios are the average of all patients in group. All the p-values shown
ange
Average log2 change
during radiotherapy —
b14 mo
Average log2 change
during radiotherapy —
N18 mo
P value
(for difference between
patient cohorts)
−0.35 −0.25 0.99
−1.21 −0.17 0.001
0.63 0.12 0.42
−0.85 0.07 0.005
0.65 −0.26 0.005
0.78 −0.79 0.01
2.20 0.06 0.01
0.68 0.02 0.02
−0.88 0.30 0.05
Fig. 3. Veriﬁcation of putative biomarkers in additional cohort and with orthogonal method. (a) Scatter plots of concentration of LBP, LRG1 and CRP in plasma with small cell lung cancer
prior to radiotherapy (SCLC—circle), adenocarcinomaNSCLC (AC—square) or squamous cell carcinomaNSCLC (SqCC—triangle). Levels of the proteins in plasmawere assayed by commer-
cial ELISA. (b) Scatter plots of the concentration of LRG1, CRP and LBP in plasma from SqCC patients prior to radiotherapy comparing survival b14 mo (circle) and N18 mo (square).
(c) Scatter plots of the concentration of LRG1, CRP and LBP in plasma from SqCC patients during radiotherapy comparing survival b14 mo (circle) and N18 mo (square). (d) Scatter
plots of the concentration of LRG1, CRP and LBP in plasma from AC and SCLC during radiotherapy comparing survival b14 mo (circle) and N18 mo (square). Signiﬁcance was tested
using a 2-tailed unpaired Mann Whitney test.
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Fig. 4. Combination of LRG1 and CRP as amultiplexed biomarker can discriminate between survival groups andmay add value to the use of gross tumour volume as a predictor of survival.
Scatter plots of survival less than 14mo (circle) andmore than 18mo (squares) compared to (a) combined levels of CRP and LRG1 in the plasma of SqCC patients during radiotherapy and
(b) gross tumour volume (cm3). Signiﬁcance was tested using a 2-tailed unpaired Mann Whitney test.
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ference (p = 0.0317) between the two survival groups but could not
fully discriminate all the patients (Fig. 4b).
3.3. Acute Phase Response in Isolation is Unlikely to be Responsible for
Elevation of the Putative Biomarkers LBP and CRP
To understand the biological process that may cause or be related to
the changes observed in b14 mo survival patients in response to radio-
therapywe analysed the contexts inwhich CRP and LBPmay change. In-
genuity analysis showed that the acute phase response pathway is
enriched in the identiﬁed dataset with 29 proteins from the pathway
seen (see Fig. 5), however only CRP showed the expected difference be-
tween outcomes consistent with this pathway taking into account p
value alone (Table 2). This indicates that the increased levels of CRP in
b14 mo survival patients may not be due to a general increase in the
acute phase response. In the acute phase response CRP and LBP are
both potentially regulated by changes in the levels of Interleukin 6 (IL-
6) (Ganapathi et al., 1990; Castell et al., 1989; Castell et al., 1988;
Moshage et al., 1988; Dentener et al., 2000; Grube et al., 1994). Further-
more a previous study identiﬁed IL-6 as a possible predictivemarker for
survival radiotherapy (Dehing-Oberije et al., 2011). The level of IL-6was
available for eight of the squamous cell carcinoma patients during treat-
ment and so its correlation with CRP, LRG1 and LBP was investigated
during radiotherapy. The correlation coefﬁcient with IL-6 was signiﬁ-
cant for CRP with 0.86 (p value 0.006) and LRG1 0.751 (p value 0.032)
but not for LBP with 0.52 (p value 0.191).
4. Discussion
In the treatment of anymalignant disease with radiotherapy there is
associated morbidity and mortality. The onset of next generation se-
quencing and other approaches in clinical medicine will in the future
potentially enable the tailoring of RT treatment. We remain some dis-
tance from that objective. The peripheral blood of patients with cancers
has yielded some markers of risk (Chaturvedi et al., 2010; Oh et al.,
2011) and as such there is sound scientiﬁc reason to search for others
that may indicate aspects of the response to radiotherapy.
Systematically collected samples with the use of a standard operat-
ing procedure in sufﬁcient numbers for biomarker analysis are difﬁcult
to obtain. However, we have devised a system where a sufﬁciently
powered study needs relatively few samples (Zhou et al., 2012). This al-
lows a serious beginning to biomarker discoverywhere the Bayesian ap-
proach of accretion of information and testing can take us towards a
panel of biomarkers. Therefore our proteomics pipeline can assist in de-
veloping personalised approaches to the treatment of lung cancer. Our
speciﬁc approach relied on high endmass spectrometry with 8 channel
isobaric tagging for relative quantiﬁcation and the use of referencestandard to allow intra experiment comparisons. Reproducible deple-
tion of major protein constituents allows deeper penetration into the
proteome, with low level constituents identiﬁed. Technical variation of
the workﬂow is very low with selection of high conﬁdence peptide
spectral matches ensuring that quantiﬁcation is only calculated from
good quality matches, reducing technical variation and ensuring low
false discovery rates. The largest variation present in the samples for
these types of studies being inter person variation, a longitudinal ap-
proachwith two baseline samples allows the variation for a speciﬁc pro-
tein to be assessed, thus reducing its impact. With a pre- and during-
treatment sample the relative expression of a protein within a patient
sample can be calculated allowing differences in an individual proteome
to be monitored without being lost in the background inter-person bio-
logical variation (Zhou et al., 2012; Zhou et al., 2013).
One third of lung cancer cases present with locally advanced disease
stage (stage III) and one thirdwith stage IV disease (Morgensztern et al.,
2010). The standard of care for locally advanced disease is concurrent
chemo-radiotherapy (Auperin et al., 2010) but the majority are not
suitable for this approach due to comorbidities and advanced age (De
Ruysscher et al., 2009). An alternative treatment is sequential chemora-
diotherapy. The patients included in this studywere at least stage 3 and
were being treated with sequential chemoradiotherapy and so are rep-
resentative of a standard care population for this disease (Reck et al.,
2013). The radiotherapy treatment was received by patients in our
study over 4–6.5 weeks, with samples collected early during treatment.
The biomarkers discovered have the potential to stratify patients into
two groups, based on survival, at an early stage of treatment and possi-
ble help tailored treatment for patients in respect of radiotherapy.
Studies on a prognostic model in NSCLC patients undergoing chemora-
diotherapy treatment have previously been performed. This took into
account ﬁve clinical variables (gender, performance status, forced expi-
ratory volume, number of lymph node stations and tumour volume)
(Dehing-Oberije et al., 2009), the performance of this model was im-
proved upon the addition of two blood borne biomarkers CEA and IL-6
(Dehing-Oberije et al., 2011). These two markers were identiﬁed by
subjective choice of candidate proteins and so it would be of interest
to see if LRG1 and LBP levels during radiotherapy would add to this
model.
We have presented data showing the discovery proteomic identiﬁ-
cation of three plasma proteins which are putative predictive marker
of survival for SqCC NSCLC patients after radiotherapy. The level of
two of these proteins (LRG1 and CRP) has been shown to be predictive
with regard to survival, with elevation indicative of reduced survival
time. A combined level of over 140 mg/L in plasma was found in all of
the patients with shorter survival. The validation was carried out
using a non-MS orthogonal antibody-based method, improving conﬁ-
dence that the differences seen are real and therefore, potentially of
use in a clinical setting. The agreement, observed in this study and
Fig. 5. The acute phase response is not generally up regulated in patients with b14mo survival. The acute phase response pathway adapted from ingenuity software, highlighting the po-
sition of IL6 (blue circle) and the proteins identiﬁed in this study (purple) with up regulated proteins (red).
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use of an isobaric tagging approaches to the identiﬁcation of novel bio-
markers in bodily ﬂuid before validation by other methods like ELISA.
One of the biomarkers we have highlighted, CRP, has previously
been proposed as an agent allowing monitoring of chronic inﬂamma-
tion (reviewed Volanakis, 2001) and also been studied as a possible bio-
marker of lung cancer risk (Chaturvedi et al., 2010; VanHemelrijck et al.,
2011). Elevated levels of circulating CRPwere associatedwith increased
risk of lung cancer; elevated levels were observed up to 5 years pre-
diagnosis. Since chronic inﬂammation has been proposed to generate
an environment advantageous to cancer survival, as well as promoting
tumourogenesis (NSCLC reviewed in O'Callaghan et al., 2010) the iden-
tiﬁcation of CRP as a risk factor may be due to chronic inﬂammation.Thus, because of the non-speciﬁc nature of circulating CRP levels
Hemelrijick and colleagues measured multiple time points of CRP and
observed that this increased conﬁdence in the link between elevation
of CRP and lung cancer risk (Van Hemelrijck et al., 2011). Our study
also allowed multiple reading of CRP, thus allowing the increase in
this protein during radiotherapy treatment to be observed; therefore
multiple time points should be implemented into any potential future
studies. The levels of CRP which indicated risk of lung cancer in the
study byHemelrijick and colleagueswas over 10mg/mL. It is worth not-
ing that the elevated levelswe see during radiotherapy are higher (up to
80 mg/L), with the pre radiotherapy levels averaging 34 mg/mL. In
NSCLC elevated levels of plasma CRP has been linkedwith poor progno-
sis for patients undergoing surgical resection and chemotherapy. But to
Table 2
Protein idenﬁed from the acute phase response. Table includes acute phase response pro-
teins identifed in investigation with expected change of direction with activation of the
acute phase response. P value indicates signiﬁcant difference between b14 mo and N18
mo survival patient groups.
Protein (gene symbol) P value Observed direction
of change during
radiotherapy
Expected direction
of change during
radiotherapy
CRP 0.01 ↑ ↑
LBP 0.42 ↑ ↑
F2 0.97 ↑
HPX 0.99 ↑
VWF 0.99 ↑
CP 0.73 ↑
PLG 0.99 ↑
ITIH4 0.05 ↑
APCS 0.72 ↑
C2 0.99 ↑
SerpinA3 0.05 ↑
C5 0.80 ↑
SerpinF 0.99 ↑
FGA 0.42 ↑
SerpinD1 1.0 ↑
C4BP 0.97 ↑
A2M 0.91 ↑
AGT 0.92 ↑
C3 0.92 ↑
C9 0.44 ↑
AHSG 0.73 ↓
TTR 0.64 ↓
ApoH 0.96 ↓
ApoA2 0.78 ↓
AMBP 0.94 ↓
HRG 0.96 ↓
849M.J. Walker et al. / EBioMedicine 2 (2015) 841–850our knowledge this is the only report of CRP elevation as a potential pre-
dictive marker for survival after radiotherapy. This indicates that CRP
measurement may be useful for all lung cancer patients undergoing
treatment. Prognosis for resection and chemotherapy were indicated
by levels before treatment, where the linkwe have observed is a change
during therapy. Therefore themechanism for CRP releasemay differ be-
tween the different therapies and somore work needs to be carried out
to investigate the mechanism of the CRP elevation. CRP as a predictive
marker of survival after radiotherapy has been previously investigated
by Dehing-Oberjie and colleagues as part of a nine protein panel; they
did not see CRP levels as a signiﬁcant indicator (Dehing-Oberije et al.,
2011). However only a single time point prior to treatment was ac-
quired. We see no signiﬁcant difference in pre-treatment levels of CRP
in this study which conﬁrms their observation.
Lipopolysaccharide binding protein is another acute phase response
protein, involved in the immune response to gram negative bacteria. It
has been monitored to predict outcome for sepsis and lung injury
(Villar et al., 2009) and a study has shown it may be of use for patients
with neutropenia associated with cancer to diagnose those with gram
negative infections (Oude Nijhuis et al., 2003). Modulation of this pro-
tein has not previously been linked with lung cancer or radiotherapy
but it is known that it can be expressed by lung epithelial cells upon
stimulation by cytokines like IL-6 (Dentener et al., 2000). Therefore
the LBP increase seen during treatment could be as a result IL-6 stimu-
lation of the lung epithelial rather than an immune challenge. Previous
reports have shown that IL-6 can be expressed in lung cancer cell lines
and the lungs of patients after radiotherapy (Zhang et al., 1994). Mea-
surement of IL-6 in the plasma of the patients during radiotherapy in
our study showed some correlation with the level of CRP and LRG1,
but not LBP. Previously it has been reported that elevated IL-6 plasma
levels prior to treatment have been associated with poor prognosis for
radiotherapy patients (Dehing-Oberije et al., 2011). With our ﬁndings,
more investigation is required into whether CRP and LRG1 levels
alone can be independent predictors of survival or whether a panel in-
cluding IL-6 would have greater predictive ability. The identiﬁcation ofCRP and LBP in this study and IL-6 previously (Dehing-Oberije et al.,
2011) as indicators of response to radiotherapy suggests that inﬂamma-
tion could be an important factor in radiotherapy response either
through tumour response or radiotherapy toxicity. IL-6 levels have pre-
viously been shown to be associatedwith lung toxicity (Siva et al., 2014)
and so itwould be interesting to see if CRP and LRG1modulation in plas-
ma could indicate radiotherapy linked toxicity.
The levels of LRG1 have been shown to be elevated in the serum and
urinary exosomes of lung cancer patients (Li et al., 2011; Liu et al., 2012)
with this protein also being identiﬁed in lung tumour tissue. The role of
LRG1 is not fully understood, although it is of interest due to its role in
angiogenesis; where it acts as a pro-angiogenic factor modulating the
role of TGF-β (Wang et al., 2013). Wang and colleagues have also
shown that angiogenesis can be reduced by the inhibition of LRG1 and
so it is a possible therapeutic target for regulation of angiogenesis. It is
known that during radiotherapy angiogenic factor expression is modu-
lated with a correlative increase in angiogenesis (Soﬁa Vala et al., 2010;
Gu et al., 2013). Therefore the ﬁnding that LRG1 is elevated in lung can-
cer patients with poor response to radiotherapy indicates it may have
three clinical uses: as a therapeutic target to increase the efﬁcacy of ra-
diotherapy, as a tool to stratify patients who require angiogenesis inhib-
itors in combination with radiotherapy (Wang et al., 2013) and as
shown in this study as a biomarker for poor prognosis.
5. Conclusion
We have identiﬁed two potential protein blood borne predictive
markers for survival which could be used to stratify patients with squa-
mous cell carcinoma early during radiotherapy. They have been veriﬁed
on an additional independent cohort of patients using ELISA. However
larger studies need to be carried out and further analyses should be
done integrating standard clinical factors predictive for survival after RT
such as extent of lymph node involvement and performance status. Final-
ly such predictive models will need to be validated on external cohorts.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.06.013.
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